携带相同F8突变的轻/中度血友病A患者基线凝血因子VIII浓度的变异:一项回顾性队列研究
该回顾性队列研究从INSIGHT和RISE研究中纳入346例携带至少10例患者共有的F8错义突变的轻/中度血友病A患者,评估基线FVIII:C的变异及决定因素。年龄和基因型解释了59%的个体间变异,个体内变异解释了相同突变患者中45%的变异。结果表明基线FVIII:C水平并非仅由F8基因型决定。
要点
- 年龄和基因型解释了轻/中度血友病A患者基线FVIII:C个体间变异的59%。
- 个体内变异解释了相同突变患者中基线FVIII:C变异的45%。
- 与Arg612Cys突变患者相比,8种其他F8错义突变患者的FVIII:C存在显著差异。
核心结论
- 轻/中度血友病A患者的基线FVIII:C水平并非仅由F8基因型决定,其他因素可能为治疗提供潜在新靶点。
研究设计与样本
- 回顾性队列研究,从纳入欧洲、加拿大和澳大利亚3534例轻/中度血友病A患者的INSIGHT和RISE研究中,选取346例携带至少10例患者共有的F8错义突变的患者。
- 基线FVIII:C采用一步法凝血测定,统计方法包括Levene检验、单变量和多变量线性回归及混合模型分析。
主要发现
- 年龄和基因型共同解释了59%的基线FVIII:C观察变异。
- 与Arg612Cys突变患者相比,8种其他F8错义突变患者的FVIII:C存在显著差异。
- 个体内变异解释了相同突变患者中45%的基线FVIII:C观察方差。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Essentials Factor VIII levels vary in mild and moderate hemophilia A (MHA) patients with the same mutation. We aimed to estimate the variation and determinants of factor VIII levels among MHA patients. Age and genotype explain 59% of the observed inter-individual variation in factor VIII levels. Intra-individual variation accounted for 45% of the variation in the three largest mutation groups. SUMMARY: Background The bleeding phenotype in patients with mild/moderate hemophilia A (MHA) is inversely associated with the residual plasma concentration of factor VIII (FVIII:C). Within a group of patients with the same F8 missense mutation, baseline FVIII:C may vary, because, in healthy individuals, von Willebrand factor (VWF) levels, ABO blood group and age are also known to influence baseline FVIII:C. Our understanding of the pathophysiologic process of the causative genetic event leading to reduced baseline FVIII:C in MHA patients is still limited. Objectives To estimate the variation and determinants of baseline FVIII:C among MHA patients with the same F8 missense mutation. Methods Three hundred and forty-six patients carrying mutations that were present in at least 10 patients in the cohort were selected from the INSIGHT and the RISE studies, which are cohort studies including data of 3534 MHA patients from Europe, Canada, and Australia. Baseline FVIII:C was measured with a one-stage clotting assay. We used Levene's test, univariate and multivariate linear regression, and mixed-model analyses. Results For 59% of patients, the observed variation in baseline FVIII:C was explained by age and genotype. Compared to FVIII:C in patients with Arg612Cys, FVIII:C was significantly different in patients with eight other F8 missense mutations. Intra-individual variation explained 45% of the observed variance in baseline FVIII:C among patients with the same mutation. Conclusion Our results indicate that baseline FVIII:C levels are not exclusively determined by F8 genotype in MHA patients. Insights into other factors may provide potential novel targets for the treatment of MHA.
引用
- Loomans JI, van Velzen AS, Eckhardt CL, et al. Variation in baseline factor VIII concentration in a retrospective cohort of mild/moderate hemophilia A patients carrying identical F8 mutations. J Thromb Haemost. 2017. PMID: 27943580. doi:10.1111/jth.13581
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。